Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31
Swedish (OMX) Biotech Industry Analysis
UpdatedMay 31, 2023
DataAggregated Company Financials
Companies70
- 7D-5.8%
- 3M-4.8%
- 1Y1.3%
- YTD1.3%
Over the last 7 days, the Biotech industry has dropped 5.8%, driven by Swedish Orphan Biovitrum declining 7.0%. On the other hand Xbrane Biopharma is actually up 6.1%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 36% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 31 May 2023 | kr165.2b | kr26.3b | -kr1,210,442,677.00 | 45.2x | -136.5x | 6.3x |
| Fri, 28 Apr 2023 | kr174.9b | kr25.5b | -kr2,144,449,920.00 | 37.1x | -81.6x | 6.9x |
| Sun, 26 Mar 2023 | kr165.5b | kr25.4b | -kr2,031,671,425.00 | 39.2x | -81.5x | 6.5x |
| Tue, 21 Feb 2023 | kr173.3b | kr25.4b | -kr2,098,281,283.00 | 37.8x | -82.6x | 6.8x |
| Thu, 19 Jan 2023 | kr179.5b | kr23.8b | -kr1,842,380,755.00 | 32.4x | -97.4x | 7.5x |
| Sat, 17 Dec 2022 | kr158.6b | kr23.8b | -kr1,838,040,816.00 | 31.2x | -86.3x | 6.7x |
| Mon, 14 Nov 2022 | kr156.0b | kr23.9b | -kr1,903,452,996.00 | 32.9x | -82x | 6.5x |
| Wed, 12 Oct 2022 | kr150.9b | kr22.9b | -kr3,333,549,724.00 | 30.5x | -45.3x | 6.6x |
| Fri, 09 Sep 2022 | kr157.2b | kr22.9b | -kr3,244,410,512.00 | 34.3x | -48.5x | 6.9x |
| Sun, 07 Aug 2022 | kr169.8b | kr22.7b | -kr3,502,700,170.00 | 35.8x | -48.5x | 7.5x |
| Tue, 05 Jul 2022 | kr155.5b | kr21.4b | -kr3,521,686,236.00 | 36.7x | -44.2x | 7.3x |
| Thu, 02 Jun 2022 | kr156.0b | kr21.4b | -kr3,524,128,445.00 | 43.3x | -44.3x | 7.3x |
| Sat, 30 Apr 2022 | kr153.5b | kr20.0b | -kr3,342,880,997.00 | 46x | -45.9x | 7.7x |
| Mon, 28 Mar 2022 | kr165.6b | kr19.7b | -kr3,081,724,978.00 | 50.5x | -53.7x | 8.4x |
| Wed, 23 Feb 2022 | kr154.6b | kr19.7b | -kr2,536,169,254.00 | 48.7x | -61x | 7.9x |
| Fri, 21 Jan 2022 | kr172.3b | kr19.1b | -kr2,041,522,338.00 | 52.2x | -84.4x | 9x |
| Sun, 19 Dec 2021 | kr188.2b | kr19.0b | -kr1,992,145,647.00 | 52.7x | -94.5x | 9.9x |
| Tue, 16 Nov 2021 | kr202.0b | kr19.0b | -kr1,429,189,004.00 | 55.5x | -141.3x | 10.6x |
| Thu, 14 Oct 2021 | kr196.8b | kr18.1b | -kr1,332,320,458.00 | 39x | -147.7x | 10.9x |
| Sat, 11 Sep 2021 | kr219.2b | kr18.1b | -kr1,339,275,285.95 | 53.8x | -163.6x | 12.1x |
| Mon, 09 Aug 2021 | kr194.8b | kr18.1b | -kr1,175,418,285.95 | 58x | -165.7x | 10.8x |
| Sun, 02 May 2021 | kr157.4b | kr17.8b | -kr1,319,393,930.10 | 43.4x | -119.3x | 8.9x |
| Wed, 03 Feb 2021 | kr154.5b | kr18.7b | -kr828,534,964.85 | 52.4x | -186.4x | 8.3x |
| Sat, 07 Nov 2020 | kr145.3b | kr19.1b | -kr517,575,173.07 | 45.7x | -280.8x | 7.6x |
| Fri, 31 Jul 2020 | kr146.2b | kr19.1b | kr12.7m | 46x | 11493.9x | 7.6x |
Price to Earnings Ratio
197.3x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.2x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 11% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -1.80% | |
| Healthcare | -2.92% | |
| Biotech | -5.82% | |
| Biotech | -5.82% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| XBRANE Xbrane Biopharma | kr78.40 | 6.1% +kr257.8m | 17.9% | PS39.8x | |
| BIOG B BioGaia | kr98.60 | 1.1% +kr106.0m | 2.3% | PE24.1x | |
| ACE Ascelia Pharma | kr16.72 | 11.9% +kr60.0m | -18.4% | PB3.9x | |
| ACTI Active Biotech | kr0.83 | 29.8% +kr50.6m | -28.0% | PB9.6x | |
| PROGEN Prostatype Genomics | kr0.50 | 47.1% +kr19.0m | -87.6% | PS87x |
